Browse all theories tagged with this keyword
The 3 August 1977 hearing prints San Francisco and New York safe houses, two-way mirrors, and a line reading midnight and climax, while Turner says the facts are not final and will not draw the conclusion asked. Two clippings use Operation Midnight Climax, mention LSD in their words, and print one hundred dollars, with no milligram or victim name. A Bay Area transcript adds Chestnut Street and Telegraph Hill. A 26 August 1977 Post clipping describes the apartment and does not print the code name. A 1978 note names a New York house. The file is not merged into another MKULTRA subproject.
The 5 April 1950 memorandum asks for teams using the polygraph, drugs, and hypnotism, prices a year at 65,515 dollars, and holds positive hypnotism for the Director's approval. A 1975 memorandum remembers BLUEBIRD drug and hypnosis work in 1949-50 and does not place a November 1953 LSD death under that name. The 1977 hearing lists four objectives, an August 1951 rename to ARTICHOKE, and MKULTRA from 1953. A briefing-book note instead assigns Frank Olson's death to MKULTRA. April 1952 and 1953 pages describe ARTICHOKE, not a BLUEBIRD experiment log.
Project MKULTRA, approved by Allen Dulles in April 1953 on a proposal from Richard Helms, paid for CIA research into drugs and other means of controlling behavior, including LSD given to people who did not know they were being tested. The Inspector General urged an end to unwitting tests in 1963, and the Rockefeller Commission called them clearly illegal in 1975. Church Committee investigators learned the files had been destroyed in 1973 on Helms's order; Turner told the 1977 hearing that surviving finance records listed 185 outside researchers and assistants and 80 institutions.
Terence McKenna described smoked DMT as entry to a hyperspace peopled by "machine elves," and Rick Strassman, who ran DMT studies in New Mexico from 1990 to 1995, wrote that the drug might let the brain perceive realms of conscious entities. Clinical work has studied the experience itself: a 2006 Hopkins trial found mystical-type effects from psilocybin, a 2020 survey logged 2,561 entity reports and beliefs, and the FDA granted psilocybin therapy a breakthrough designation in 2018 and issued trial guidance in 2023.